Efsubaglutide Alfa: Innogen GLP-1 Results and US Status

The short answer

Efsubaglutide alfa (also called supaglutide) is a long-acting GLP-1 shot made by Innogen Pharmaceuticals in China. It is approved in mainland China and Macao for type 2 diabetes, not for weight loss, and it is not approved in the US. In an 18-week trial in adults with overweight or obesity, the once-weekly 20 mg dose cut body weight by about 10.6% on average. On November 19, 2026, Innogen licensed it to Arcera Life Sciences for parts of Africa, Eastern Europe, Latin America and the Middle East in a deal worth over $1 billion. Whatever GLP-1 you end up on, protecting muscle is your job, and Sharpy gives you one protein target and one 20-minute workout a day.

What is efsubaglutide, and is it a new weight-loss shot you can get? Efsubaglutide alfa (also spelled "efsubaglutide α" and called supaglutide) is a long-acting GLP-1 injection from Innogen Pharmaceuticals in China. It is approved in mainland China and Macao for type 2 diabetes only. It is not approved in the US or Europe. The name jumped into the news on November 19, 2026, when Innogen signed a licensing deal worth over $1 billion to take it to new markets.

Here is what the drug is, what the trials showed, and what the deal means if you live in the US.

Efsubaglutide alfa at a glance

Question Answer
Generic name Efsubaglutide alfa (efsubaglutide α), also called supaglutide
Chinese brand name 怡诺轻 (no English brand name yet)
Maker Innogen Pharmaceuticals (HKEX: 2591)
Drug type GLP-1 receptor agonist, GLP-1 fused to an antibody Fc fragment
How it is given Injection; trials tested once a week and every two weeks
Approved for Blood sugar control in adults with type 2 diabetes
Approved where Mainland China and Macao
Weight-loss approval None yet
US / FDA status Not approved
Latest news Licensed to Arcera Life Sciences on November 19, 2026

How efsubaglutide works

Efsubaglutide alfa acts like the GLP-1 hormone your gut makes after a meal. It helps the pancreas release insulin when blood sugar is high and lowers glucagon, a hormone that raises blood sugar. That is the same family as semaglutide (Ozempic, Wegovy).

The difference is the build. China's NMPA says the drug is human GLP-1 joined to the Fc piece of a human IgG2 antibody. The Fc piece keeps the drug in the blood much longer, which is why Innogen calls it "ultra-long-acting" and is testing doses spaced two weeks or even four weeks apart. Dulaglutide (Trulicity), a weekly diabetes shot sold in the US, uses a similar Fc idea.

Efsubaglutide alfa weight loss: the ENLIGHT trial

ENLIGHT is a Phase IIb/III trial in about 200 Chinese adults with overweight or obesity and no diabetes. It is placebo-controlled and double-blind, and it tested doses from 5 mg to 20 mg. Innogen presented the 18-week Phase IIb results at the 2026 American Diabetes Association meeting.

Result after 18 weeks 20 mg once weekly 20 mg every two weeks
Average weight loss About 10.6% About 9.7%
Waist size About 8.9 cm (3.5 in) smaller Not reported
Liver fat Down by up to about half Not reported
Low blood sugar events None reported None reported
Stopped due to side effects No one No one

Three things to keep in mind:

  • These are company numbers. They come from Innogen's press releases, not a peer-reviewed paper.
  • The placebo result is missing. The company has not shared how much the placebo group lost, so the true drug effect is not clear yet.
  • 18 weeks is short. Innogen says weight was still dropping at the end, with no plateau. Longer data will come from the Phase III part of the same study.

Innogen also says the weight lost was mostly fat and that the muscle-to-fat ratio rose by up to 45% from baseline. That is a good sign, but it is an early company claim. Our tirzepatide muscle loss guide shows how much lean mass people lose on approved GLP-1 drugs and why it matters.

What it did for type 2 diabetes

For diabetes, the drug's approved use, Innogen reports that HbA1c (the three-month blood sugar number) fell by about 1.1 points after four weeks and by up to 2.2 points at week 24 when used alone. A study called SUPER 2 on blood sugar and beta-cell function was published in Nature Communications in May 2026. The drug is on China's 2025 national reimbursement drug list, so it is covered by Chinese public insurance for diabetes.

Efsubaglutide vs semaglutide and tirzepatide

There is no head-to-head trial. The table below shows each drug's best-known weight-loss result next to each other, but the trials differ in length, people and design, so they are not a fair contest.

Drug Trial Length Average weight loss
Efsubaglutide alfa 20 mg weekly ENLIGHT (Phase IIb) 18 weeks About 10.6% (placebo not disclosed)
Semaglutide 2.4 mg (Wegovy) STEP 1 68 weeks 14.9% (placebo 2.4%)
Tirzepatide 15 mg (Zepbound) SURMOUNT-1 72 weeks 20.9% (placebo 3.1%)

Early weight loss on GLP-1 drugs usually keeps going for many months, so an 18-week number will likely grow. How far it grows is unknown until the longer data is out. For other new GLP-1s still in testing, see our guides to survodutide, VK2735 and the ASC30 pill.

The Arcera deal: what was announced

On November 19, 2026, Innogen signed an exclusive licensing deal with Arcera Life Sciences, a company based in Abu Dhabi.

  • Where: Selected countries in Africa, Eastern Europe, Latin America and the Middle East. Innogen keeps the rights everywhere else.
  • Money: $38 million in upfront and near-term milestone payments, including $15 million upfront that does not have to be paid back. Sales milestones and royalties could push the total past $1 billion.
  • Who does what: Arcera handles approvals, market access and sales in those countries.

The US, Canada, the UK and the EU are not part of this deal.

Can you get efsubaglutide in the US?

No. It has no FDA approval, and no US trial or FDA filing has been announced. Innogen has run a Phase II study in Australia testing once-a-month dosing, but that is a trial, not an approval. Any website selling "efsubaglutide" or "supaglutide" to US buyers is selling an unapproved product. Do not buy it.

If you want a GLP-1 now, the approved options are drugs like Wegovy, Zepbound and the newer pills. Talk to your prescriber about which fits you.

What to do while new drugs come along

New GLP-1s keep arriving, but the basics of losing weight well do not change. Every drug in this class can take muscle along with fat, so eating enough protein and lifting a few times a week matter on any of them. Sharpy turns that into one daily protein target, one 20-minute workout, and a Shape Score that tracks whether you are losing fat or muscle.

What to watch next

  • Full ENLIGHT results, including the placebo number and longer Phase III data.
  • Which countries Arcera files in first.
  • Whether Innogen seeks a weight-loss approval in China.
  • Any move toward an FDA filing, which has not been announced.

Facts here are current as of November 20, 2026. If you are already on a GLP-1, Sharpy keeps your protein and workouts in one place while you wait to see what comes next.

Sources

Questions people ask

What is efsubaglutide alfa?

Efsubaglutide alfa is a GLP-1 receptor agonist injection. China's drug regulator (NMPA) describes it as human GLP-1 fused to the Fc fragment of human IgG2, a design that makes it last a long time in the body. It is sold in China under the Chinese trade name 怡诺轻 for blood sugar control in adults with type 2 diabetes.

What company makes efsubaglutide?

Innogen Pharmaceuticals (Hong Kong stock code 2591), based in China, developed it in-house. China's NMPA notice names Shanghai Yinnuo Pharmaceutical Technology as the company holding the approval. On November 19, 2026, Innogen licensed it to Arcera Life Sciences of Abu Dhabi for selected countries in Africa, Eastern Europe, Latin America and the Middle East.

How much weight do you lose on efsubaglutide alfa?

In the Phase IIb ENLIGHT trial in Chinese adults with overweight or obesity, the 20 mg once-weekly dose lowered body weight by about 10.6% on average after 18 weeks, and 20 mg every two weeks lowered it by about 9.7%. These numbers come from Innogen's announcements. The trial had a placebo group, but the company has not said how much the placebo group lost.

Is efsubaglutide FDA approved?

No. As of November 20, 2026, efsubaglutide alfa is not approved by the FDA or the EMA for any use. It is approved only in mainland China and Macao, and only for type 2 diabetes. You cannot get it legally from a US pharmacy.

Efsubaglutide vs semaglutide: which is better?

No study has tested them head to head, so nobody can say. Efsubaglutide alfa lowered weight about 10.6% in 18 weeks in its Phase IIb trial. Semaglutide 2.4 mg (Wegovy) lowered weight about 14.9% over 68 weeks in the STEP 1 trial. Different lengths, people and designs make the numbers hard to compare.

What are the side effects of efsubaglutide alfa?

Innogen says stomach side effects in ENLIGHT were mostly mild to moderate and short-lived, no low blood sugar events happened, and no one stopped treatment because of side effects in the 18 weeks. A full side-effect table has not been published in English. As with other GLP-1 drugs, nausea, vomiting, diarrhea and constipation are the ones to expect.

Read next